Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses

##STR00001##

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses

##STR00001##

The present invention relates compounds comprising a tetra-heteroaryl indacenodithiophene-based structural unit, the synthesis of such compounds as well as their use in organic electronic devices. The invention further relates to organic electronic devices comprising such compounds.

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses. ##STR00001##

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses. ##STR00001##

A polymer compound comprising a structural unit represented by the formula (1):

##STR00001## wherein a ring A and a ring B represent a heterocyclic ring. A ring C represents a condensed aromatic heterocyclic ring not having a line-symmetric axis and a rotational axis. Z.sup.1 and Z.sup.2 represent a group represented by the formula (Z-1), a group represented by the formula (Z-2), a group represented by the formula (Z-3), a group represented by the formula (Z-4), a group represented by the formula (Z-5), a group represented by the formula (Z-6) or a group represented by the formula (Z-7).

##STR00002## R represents an alkyl group, a cycloalkyl group, an alkoxy group, a cycloalkoxy group, an alkylthio group, a cycloalkylthio group, an aryl group or a monovalent heterocyclic group.].

Disclosed are an electrode active material for a power storage device and a power storage device including the same. The electrode active material includes a polymer that includes: a tetravalent group derived from a compound selected from the group consisting of EBDT and derivatives thereof, TTF and derivatives thereof, a condensation product of EBDT and TTF and derivatives thereof, and a TTF dimer and derivatives thereof; and a divalent group S-A-S where A is a divalent aliphatic group or a divalent group represented by the formula -E-D-E- where D represents a divalent alicyclic group, a divalent aromatic group, or a carbonyl group, and two Es each independently represent a divalent aliphatic group. Adjacent two tetravalent groups mentioned above are linked by one or two divalent groups mentioned above.

Disclosed are an electrode active material for a power storage device and a power storage device including the same. The electrode active material includes a polymer that includes: a tetravalent group derived from a compound selected from the group consisting of EBDT and derivatives thereof, TTF and derivatives thereof, a condensation product of EBDT and TTF and derivatives thereof, and a TTF dimer and derivatives thereof; and a divalent group S-A-S where A is a divalent aliphatic group or a divalent group represented by the formula -E-D-E- where D represents a divalent alicyclic group, a divalent aromatic group, or a carbonyl group, and two Es each independently represent a divalent aliphatic group. Adjacent two tetravalent groups mentioned above are linked by one or two divalent groups mentioned above.

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.

##STR00001##

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.

##STR00001##